Your browser doesn't support javascript.
loading
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
Maraveyas, A; Waters, J; Roy, R; Fyfe, D; Propper, D; Lofts, F; Sgouros, J; Gardiner, E; Wedgwood, K; Ettelaie, C; Bozas, G.
Affiliation
  • Maraveyas A; Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Cottingham, UK. Anthony.maraveyas@hey.nhs.uk
Eur J Cancer ; 48(9): 1283-92, 2012 Jun.
Article in En | MEDLINE | ID: mdl-22100906
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Dalteparin / Deoxycytidine / Venous Thromboembolism / Anticoagulants / Antimetabolites, Antineoplastic Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2012 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Dalteparin / Deoxycytidine / Venous Thromboembolism / Anticoagulants / Antimetabolites, Antineoplastic Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2012 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido